Hello, everyone, and how are you today? A dank cloudy cover greeted us this morning, but we are ignoring the gloom by keeping busy. After all, there is much to be done. There are deadlines to meet, a variety of reading material to digest, and calls to make. We trust you can relate. So please join us as we fortify ourselves with more cups of stimulation — we are back to blueberry cobbler — and get started. Hope you conquer the world and accomplish much. And of course, be in touch. …
Over the last six years, a venture capital team run by Bayer invested roughly $1.5 billion into small biotech startups and now the unit is ramping up with plans to invest a nearly identical pot of money — this time, $1.3 billion — in half the time, according to STAT. Bayer launched its venture arm, Leaps by Bayer, in 2015. The team scouts out startups that the drugmaker could invest in and potentially make a bit of money. But more importantly, its mandate is to find biotech and agriculture startups that might one day make for interesting R&D partners, or acquisition targets.
Novartis plans to make growth in the U.S. its top geographic priority, even after laws were passed to rein in drug prices in the world’s largest pharmaceutical market, Reuters writes. As part of an investor event on Thursday, the company indicated it would adopt a “U.S.-first mindset,” increase the share of U.S. patients in clinical trials, build capability in the country, and give U.S. staff and executives more say and better career opportunities within the organization. At the same time, Novartis aims to be a top-three player in China, up from fifth place last year among multinational pharmaceutical companies.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect